About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

5G-PEARL: Paxalisib in Malignant Brain Tumours | Clinical Trials | Clareo Health

RECRUITINGPhase 1/2

5G-PEARL: Paxalisib in Malignant Brain Tumours

5G-PEARL: Paxalisib in Combination With Temozolomide in Patients With High Grade Malignant Brain Tumours Within the 5G Platform

NCT07391215•Institute of Cancer Research, United Kingdom

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Malignant Primary GliomasGlioblastoma Multiforme (GBM)

Interventions

Paxalisib

Temozolomide capsule

Locations

1

United Kingdom

Locations (1)

Royal Marden NHS Foundation Trust

Sutton, United Kingdom

Key Dates

Start Date

January 19, 2026

Primary Completion Date

January 19, 2029

Completion Date

June 30, 2029

Last Updated

February 5, 2026

Related Studies

RECRUITINGPhase 3

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

NCT07100730

Neoplastic DiseaseGlioblastoma+4 more

RECRUITINGPhase 1/2

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

NCT03213002

Glioblastoma Multiforme (GBM)Glioblastoma+7 more

Enrolling By InvitationPhase 1

The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM

NCT06616727

Recurrent Glioblastoma Multiforme (GBM)

Not Yet Recruiting

The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab

NCT07052877

GlioblastomaGlioblastoma Multiforme (GBM)

Not Yet RecruitingNA

Patient's Derived Organoids for Drug Screening in Glioblastoma

NCT06781372

GlioblastomaGlioblastoma Multiforme (GBM)+1 more

COMPLETEDPhase 1

TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM

NCT02202993

Glioblastoma Multiforme (GBM)

View all related studies

Contacts

5G Team

CONTACT

0203 437 6003 5G-enquiries@icr.ac.uk

Sponsors

Lead Sponsor

Institute of Cancer Research, United Kingdom

Collaborators

Minderoo Foundation
Kazia Therapeutics Limited
Royal Marsden NHS Foundation Trust
Cambridge University Hospitals NHS Foundation Trust
Cancer Research UK

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 5, 2026Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions